Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Regan, Kate H ^a   Bhatt, Jayesh ^b  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CEPACIA INFECTION; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CYSTIC FIBROSIS; DISEASE EXACERBATION; ERADICATION THERAPY; GENETIC DISORDER; HUMAN; LONG TERM CARE; LUNG DISEASE; LUNG FUNCTION; MORBIDITY; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; BURKHOLDERIA INFECTIONS; DISEASE ERADICATION; MICROBIOLOGY;

BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DISEASE ERADICATION; HUMANS;

EID: 84965185857     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009876.pub2     Document Type: Review

References (99)

1. Adeboyeku DU, Agent P, Jackson V, Hodson M. A double blind randomised study to compare the safety and tolerance of differing concentrations of nebulised colistin administered using HaloLite in cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2001;32 Suppl 22:288. [CFGD Register: PI165; MEDLINE: 98135729].
2. Amelina E, Senkevich N, Cherniak A, Cherniaev A, Chuchalin A. Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life [abstract]. European Respiratory Journal 2000;16 Suppl 31:123s. [CFGD Register: PI181; MEDLINE: 98135729].
3. Carswell F, Ward C, Cook DA, Speller DC. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. British Journal of Diseases of the Chest 1987;81(4):356-60. [CFGD Register: PI54].
4. Chua H, Collis G, Souef P. Bronchial response of children with cystic fibrosis to nebulised antibiotics [abstract]. Australian and New Zealand Journal of Medicine 1990;20:537. [CFGD Register: PI66b].
5. Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. European Respiratory Journal 1990;3(10):1114-6. [CFGD Register: PI66a].
6. Conway SP. Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32 Suppl:S256. [CFGD Register: PI78; MEDLINE: 98135729].
7. Cooper DM, Harris M, Mitchell I. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis [abstract]. American Review of Respiratory Disease 1985;131:A242. [CFGD Register: PI129].
8. Davis RL, Koup JR, Williams Warren J, Weber A, Heggen L, Stempel D, et al.Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915-9. [CFGD Register: PI50].
9. Degg C, Mulheran M. The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis. British Journal of Audiology 1996;30(2):99-100. [CFGD Register: PI167].
10. Dodd M, Maddison J, Abbott J, Webb AK. The effect of the tonicity of nebulised colistin on lung function in adults with cystic fibrosis [abstract]. Proceedings of the 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid, Spain. 1993:121. [CFGD Register: PI100a; MEDLINE: 98135729].
11. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52(7):656-8. [CFGD Register: PI100b; MEDLINE: 97388924].
12. Dodd ME, Maddison J, Abbot J, Webb AR. The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis [abstract]. European Respiratory Journal 1993;6 Suppl 17:515s. [CFGD Register: PI100c; MEDLINE: 98135729].
13. Dodd ME, Haworth CS, Moorcroft AJ, Miles J, Webb AK. Is medicine evidence-based when there is discrepancy between patient reported and objective measures of compliance in clinical trials? [abstract]. Pediatric Pulmonology 1998;26 Suppl 17:389-90. [CFGD Register: PI237; MEDLINE: 97388924].
14. Geller DE, Rodriguez CA, Howenstine M, Murphy T, Voter K, Nickerson B, et al.The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery time in patients with cystic fibrosis (CF) [abstract]. American Journal of American Journal of Respiratory and Critical Care Medicine 2004;169(7):A391. [CFGD Register: PI183a; MEDLINE: 98135729].
15. Rosenfeld M, Geller DE, Rodriguez CA, Howenstine M, Konstan M, Ordonez C, et al.Serum pharmacokinetics of two preparations of tobramycin solution for inhalation in young cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A386. [CFGD Register: PI183b; MEDLINE: 98135729].
16. Goldfarb J, Wormser GP, Inchiosa MA Jr, Guideri G, Diaz M, Gandhi R, et al.Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986;26(3):222-6. [CFGD Register: PI44].
17. Geller DE, Flume P, Schwab R, Fornos P, Conrad DJ, Morgan E, et al.A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:315, Abstract no: 321. [CFGD Register: PI210b; MEDLINE: 96296083].
18. Griffith DC, Hansen C, Pressler T, Balchen T, Jensen TJ, Geller DE, et al.Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications [abstract]. Journal of Cystic Fibrosis 2008;7 Suppl 2:S26. [CFGD Register: PI210a; MEDLINE: 96296083].
19. Gulliver T, Wilson S, Williams G, Harris M, Cooper D. Nebulized tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients [abstract]. Proceedings of the Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2003 April 4-9; Adelaide, Australia. 2003:Abstract no: P139. [CFGD Register: PI184; MEDLINE: 98135729].
20. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration [Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal- und Dreimalgabe.]. Klinische Padiatrie 1993;205(1):18-22. [CFGD Register: PI74].
21. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life [Intravenos antibiotikabehandling i hemmet vid cystisk fibros ger okad livskvalitet]. Lakartidningen 1988;85(18):1614-7. [CFGD Register: PI206; MEDLINE: 96296083].
22. Huang N, Palmer J, Schidlow D, Hsuan F, Hsu C, Goldberg M, et al.Evaluation of antibiotic therapy in patients with cystic fibrosis [abstract]. Chest 1979;76(3):354-5. [CFGD Register: PI113; MEDLINE: 98135729].
23. Huang NN, Palmer J, Braverman S, Keith HH, Schidlow D. Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study [abstract]. Proceedings of 23rd Annual Meeting Cystic Fibrosis Club Abstracts; 1982 May 14; Washington D.C.. 1982:124. [CFGD Register: PI114; MEDLINE: 98135729].
24. App EM, Huls G, Bittner-Dersch P, Stolz S, Lindemann H, Matthys H. Impared lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. Pediatric Pulmonology 2000;30 Suppl 20:279-80. [CFGD Register: PI156b; MEDLINE: 98135729].
25. Huls G, App EM, Bittner-Dersch P, Stolz S, Lindemann H. Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:177. [CFGD Register: PI156a; MEDLINE: 98135729].
26. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19. [CFGD Register: PI104; MEDLINE: 98135729].
27. Keller M, Coates AL, Griese M, Denk O, Schierholz J, Knoch M. In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg/1.5ml) administered by the eFlow® electronic nebuliser compared to TOBI® in the PARI LC PLUS® [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S22, Abstract no: 84. [CFGD Register: PI241; MEDLINE: 96296083].
28. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract]. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:52. [CFGD Register: PI124; MEDLINE: 98135729].
29. Junge S, Kruger K, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin - increased risk for cochlea damage in children with cystic fibrosis (CF)? [abstract]. Pediatric Pulmonology 2001;32 Suppl 22:291. [CFGD Register: PI160b].
30. Kruger K, Junge S, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin in patients with cystic fibrosis - increased risk for cochlea damage? [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P191. [CFGD Register: PI160a; MEDLINE: 98135729].
31. Labiris R, Freitag A, Pratt B, Efthimiadis A, Hargreave F, Dolovich M. Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation? [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A307. [CFGD Register: PI182; MEDLINE: 98135729].
32. Ledson MJ, Gallagher MJ, Cowperthwaite C, Robinson M, Convery RP, Walshaw MJ. A randomised double blind placebo controlled crossover trial of nebulised taurolidine in adult CF patients colonised with B Cepacia [abstract]. Proceedings of 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:120. [CFGD Register: PI128a; MEDLINE: 98135729].
33. Ledson MJ, Gallagher MJ, Robinson M, Cowperthwaite C, Williets T, Hart CA, et al.A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. Journal of Aerosol Medicine 2002;15(1):51-7. [CFGD Register: PI128b].
34. Loening-Baucke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979;95(4):630-7. [CFGD Register: PI19b].
35. Loening-Baucke VA, Mischler EH, Myers MG. Cephalexin in cystic fibrosis: a placebo-controlled study [abstract]. Pediatric Research 1978;12(4 Pt 2):495. [CFGD Register: PI19c; MEDLINE: 78335753].
36. Loening-Bauke V, Mischler EH, Myers MG. Cephalexin compared to placebo in the management of patients with cystic fibrosis [abstract]. Proceedings of 19th Cystic Fibrosis Club Abstracts; 1978. 1978:69. [CFGD Register: PI19a; MEDLINE: 98135729].
37. Nathanson I, Cropp GJA, Li P, Neter E. Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) [abstract]. Cystic Fibrosis Club Abstracts; 1985. 1985:145. [CFGD Register: PI130; MEDLINE: 98135729].
38. Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of Cystic Fibrosis 2006;5(3):153-7. [CFGD Register: PI199; MEDLINE: 98135729].
39. Postnikov SS, Semykin SIu, Kapranov NI, Perederko LV, Polikarpova SV, Khamidullina KF. Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia [Otsenka effektivnosti i perenosimosti pefloksatsina pri lechenii i profilaktike tiazhelykh infektsii u detei s mukovistsidozom i aplasticheskoi anemiei.]. Antibiotiki i Khimioterapiia 2000;45(8):25-30. [CFGD Register: PI171].
40. Postnikov SS, Semykin SJ, Najimov VP. Safety of fluoroquinolones in children [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P213. [CFGD Register: PI162; MEDLINE: 98135729].
41. Postnikov SS, Semiakin SI, Nazhimov VP, Kapranov NI. Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons [Cravnitel'naiia godovaia skorost' rosta u detei s mukovistsidozom, poluchavshikh i nepolychavshikh tsiprofloksatsin:klinicomorfologicheskie copostavleniia.]. Antibiotiki I Khimioterapiia 2001;46(10):11-3. [CFGD Register: PI169].
42. Ramstrom H, Erwander I, Mared L, Kornfalt R, Seiving B. Pharmaceutical intervention in the care of cystic fibrosis patients. Journal of Clinical Pharmacy and Therapeutics 2000;25(6):427-34. [CFGD Register: PI159].
43. Roberts GW, Nation RL, Jarvinen AO. Measurement of serum tobramycin in the presence of ticarcillin or piperacillin. Australian Journal of Hospital Pharmacy 1992;22(2):152-4. [CFGD Register: PI132b].
44. Roberts GW, Nation RL, Jarvinen AO, Martin AJ. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. British Journal of Clinical Pharmacology 1993;36:372-5. [CFGFD Register: PI132a].
45. Romano L, Minicucci L, Spallone E, Girosi D, Campelli A, Fabbri A, et al.Role of home therapy with ofloxacin in patients with cystic fibrosis (CF) [Ruolo della terapia domiciliare con ofloxacin in pazienti con fibrosi cistica (FC)]. Giornale Italiano de Chemioterapia 1991;38(1-3):181-3. [CFGD Register: PI68].
46. Romano L, Girosi D, Spallone E, Parisi F, Minicucci L, Romano C. The use of ofloxacin in cystic fibrosis patients [Uso dell'ofloxacin nei pazienti con fibrosi cistica.]. Minerva Pediatrica 1992;44(3):79-86. [CFGD Register: AB59].
47. Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio A, McNamara S, et al.Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study [abstract]. Pediatric Pulmonology 2006;41 Suppl 29:327. [CFGD Register: PI203; MEDLINE: 96296083].
48. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scandinavian Journal of Infectious Diseases 1992;24(2):215-8. [CFGD Register: PI72].
49. Smith A, Weber A, Pandher R, Williams-Warren J, Cohen ML, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106-8. [CFGD Register: PI145].
50. Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987;82 Suppl 4A:189-95. [CFGD Register: PI48b].
51. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. American Journal of Medicine 1987;82 Suppl 4A:142-5. [CFGD Register: PI48a].
52. Burns J, LiPuma JJ, Retsch-Bogart G, Bresnik M, Henig N, McKevitt M, et al.No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection [abstract]. Journal of Cystic Fibrosis 2012;11 Suppl 1:S71, Abstract no: 58. [CFGD Register: PI259d; CRS-ID: 5500100000011251].
53. Burns JL, LiPuma J, McKevitt M, Lewis S, Retsch-Bogart GZ, Bresnik M, et al.The effect of Burkholderia colony morphology in cystic fibrosis (CF) patients with chronic Burkholderia species in a randomized trial of aztreonam for inhalation solution (AZLI) [abstract]. Pediatric Pulmonology 2012;47 Suppl 35:333, Abstract no: 307. [CFGD Register: PI259g; CRS-ID: 5500100000011253].
54. Tullis E, Burns J, Retsch-Bogart G, Bresnik M, Henig N, Lewis S, et al.Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial [abstract]. Journal of Cystic Fibrosis 2012;11 Suppl 1:S11, Abstract no: WS5.4. [CFGD Register: PI259e; CRS-ID: 5500100000011249].
55. Tullis E, Burns JL, Retsch-Bogart G, Bresnik M, Henig NR, Lewis S, et al.Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic burkholderia species (Burk) infection: initial results from a randomized, placebo-controlled trial [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:296, Abstract no: 234. [CFGD Register: PI259b; CRS-ID: 5500100000011263].
56. Tullis E, Burns JL, Retsch-Bogart G, Bresnik M, Lewis S, Montgomery AB, et al.Aztreonam 75mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from randomized, placebo-controlled trial [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S22, Abstract no: 85. [CFGD Register: PI259c; CRS-ID: 5500100000011258].
57. Tullis E, Burns JL, Retsch-Bogart GZ, Bresnik M, Lewis S, LiPuma J. Lung function in cystic fibrosis (CF) patients with chronic Burholderia (Burk) species infection over the course of a prospective, randomized trial of aztreonam for inhalation solution (AZLI) [abstract]. Pediatric Pulmonology 2012;47 Suppl 35:334, Abstract no: 310. [CFGD Register: PI259f; CRS-ID: 5500100000011254].
58. Tullis E, LiPuma JJ, Retsch-Bogart G, Bresnik M, Henig N, McKevitt M, et al.Effects of continous aztreonam for inhalation solution (AZLI) use on pathogens and antibiotic susceptibility in cystic fibrosis (CF) patients with chronic Burkholderia species infection [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:305, Abstract no: 257. [CFGD Register: PI259a; CRS-ID: 5500100000011265].
59. Uluer AZ, Waltz DA, Kalish LA, Adams S, Gerard C, Ericson DA. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. Journal of Cystic Fibrosis 2013;12(1):54-9.
60. Vitti TG, Berg TJ, Pagtakhan RD. The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis [abstract]. 16th Cystic Fibrosis Club Abstracts; 1975. 1975:56. [CFGD Register: PI81; MEDLINE: 98135729].
61. Wood PJ, Ioannides Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, et al.Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51(4):369-73. [CFGD Register: PI109; MEDLINE: 96296083].
62. NCT00298922. Azithromycin in patients with CF, infected with Burkholderia Cepacia Complex. http://clinicaltrials.gov/show/NCT00298922 (accessed 28 November 2013).
63. Ball R, Brownlee KG, Duff AJ, Denton M, Conway SP, Lee TW. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI?. Journal of Cystic Fibrosis 2010;9(1):73-4.
64. Littlewood J, Dodd M, Elborn S, Geddes D, Govan J, Hart CA, et al.The Burkholderia cepacia complex. Suggestions for prevention and infection control - 2nd Edition. Report of the UK Cystic Fibrosis Trust Infection Control Group September 2004. [ISBN: 0-9540536-9-9].
65. UK CF Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis - 3rd Edition. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group May 2009. [ISBN: 0-9548511-3-7].
66. UK CF Trust. Annual Data Report 2012. UK CF Registry 2013.
67. Corey M, Farewell V. Determinants of Mortality from Cystic Fibrosis in Canada, 1970-1989. American Journal of Epidemiology 1996;143(10):1007-17.
68. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
69. Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, et al.Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. European Respiratory Journal 2009;33(2):305-11.
70. Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clinical Microbiology and Infection 2010;16(7):821-30.
71. Etherington C, Peckham DG, Conway SP, Denton M. Burkholderia cepacia complex infection in adult patients with cystic fibrosis - is early eradication possible?. Journal of Cystic Fibrosis 2003;2(4):220-1.
72. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
73. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al.Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Critical Care Medicine 2003;167(6):841-9.
74. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, et al.Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology 2007;42(7):610-23.
75. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
76. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
77. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD004197.pub3].
78. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis 2003;2(1):29-34.
79. LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clinical Microbiology Reviews 2010;23(2):299-323.
80. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LTK, et al.Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clinical Infectious Diseases 2001;33(9):1469-75.
81. Millar-Jones L, Ryley HC, Paull A, Goodchild MC. Transmission and prevalence of Burkholderia cepacia in welsh cystic fibrosis patients. Respiratory Medicine 1998;92(2):178-83.
82. Moore JE, Crowe M, Shaw A, McCaughan J, Redmond AO. Antibiotic resistance in Burkholderia cepacia at two regional cystic fibrosis centres in Northern Ireland: is there a need for synergy testing?. Journal of Clinical Microbiology 2001;48(2):319-21.
83. Moriceau S, Kantari C, Mocek J, Davezac N, Gabillet J, Guerrera IC, et al.Coronin-1 is associated with neutrophil survival and is cleaved during apoptosis: potential implication in neutrophils from cystic fibrosis patients. Journal of Immunology 2009;182(11):7254-63.
84. Moriceau S, Lenoir G, Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. Journal of Innate Immunity 2010;2(3):260-6.
85. Nzula S, Vandamme P, Govan JR. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. Journal of Antimicrobial Chemotherapy 2002;50(2):265-9.
86. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
87. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358(9286):983-4.
88. Ratjen F, Doring G. Cystic Fibrosis. Lancet 2003;361(9358):681-9.
89. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine 2006;12(6):428-32.
90. Saiman L. Microbiology of early CF lung disease. Paediatric Respiratory Review 2004;5 Suppl A:S367-9.
91. Smyth A, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD001912].
92. Sokol PA, Kooi C, Hodges RS, Cachia P, Woods DE. Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia. Journal of Infectious Diseases 2000;181(5):1682-92.
93. St Denis M, Ramotar K, Vandemheen K, Tullis E, Ferris W, Chan F, et al.Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis. Chest 2007;131(4):1188-96.
94. Sterne J, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The CochraneCollaboration, 2011. Available from www.cochrane-handbook.org.
95. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis. European Respiratory Journal 2005;26(3):458-61.
96. Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, et al.Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010;65(10):915-20.
97. Vermis K, Vandamme PA, Nelis HJ. Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. Journal of Applied Microbiology 2003;95(6):1191-9.
98. Zlosnik JEA, Costa PS, Brant R, Mori PYB, Hird TJ, Fraenkel MC, et al.Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. American Journal of Respiratory and Critical Care Medicine 2011;183(1):67-72.
99. Regan K, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009876].